Bioterrorism Evaluations
To view Evaluated Articles, you must have an active subscription (or trial) and be signed in.
If you have an active subscription (or trial), please sign in. If your access has expired, you can subscribe at $9.95 per month. If you think you should be able to access this content, please contact us.
Sign in | Free Trial | Subscribe | Recommend to Library
New to F1000? See the Top Rated article below for a free preview of one of our Evaluated Articles.
SECTION HEADS
-
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA
-
Department of Cellular Biology & Histology, Schneider Children's Medical Center of Israel, Tel-Aviv University, Ramat Aviv, Israel
-
Biomedical Sciences Department, Defence Science and Technology Laboratory, Salisbury, Wiltshire, UK
Section Topics
- » Anthrax
- » Burkholderia mallei & Burkholderia pseudomallei
- » Clostridium botulinum
- » Francisella tularensis
- » National, state & medical institutions' preparedness to bioterrorism
- » Q fever & other rickettsioses
- » Ricin toxin
- » Smallpox & other pox diseases
- » Viral encephalitides
- » Viral hemorrhagic fevers
- » Yersinia pestis
LATEST EVALUATION
TOP RATED ARTICLE THIS WEEK [FREE TO VIEW]
1 Evaluation, most recent by
Paul Johnson, Austin Health, Australia. F1000 Infectious Diseases
- New Finding
INDIVIDUALS
Get instant access to evaluations from over 10,000 experts in biology and medicine by taking a free trial or an individual subscription.
or
Already have a subscription? Sign in for instant access. If you are signed in but are not able to view content, your access has expired. Please take out a subscription or recommend F1000 to your librarian.
RECOMMENDATIONS
Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.
LIBRARIANS & INFORMATION MANAGERS
Get an extended free trial supporting clinicians and researchers at your academic or corporate institution.
FREE ACCESS
Your institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.